17.43
前日終値:
$17.84
開ける:
$17.85
24時間の取引高:
3.17M
Relative Volume:
0.50
時価総額:
$2.44B
収益:
$67.67M
当期純損益:
$-412.69M
株価収益率:
-4.555
EPS:
-3.8266
ネットキャッシュフロー:
$-395.87M
1週間 パフォーマンス:
+3.01%
1か月 パフォーマンス:
+28.73%
6か月 パフォーマンス:
+72.06%
1年 パフォーマンス:
+70.05%
Intellia Therapeutics Inc Stock (NTLA) Company Profile
名前
Intellia Therapeutics Inc
セクター
電話
857-285-6200
住所
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc
|
17.43 | 2.49B | 67.67M | -412.69M | -395.87M | -3.8266 |
|
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-02 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2025-11-12 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-11-07 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2025-10-28 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-10-27 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | アップグレード | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | 開始されました | H.C. Wainwright | Buy |
| 2025-02-28 | ダウングレード | Goldman | Neutral → Sell |
| 2025-02-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-01-27 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | ダウングレード | Goldman | Buy → Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-04-13 | 開始されました | Canaccord Genuity | Buy |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-03-14 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-01-24 | アップグレード | Citigroup | Sell → Neutral |
| 2023-01-19 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | 開始されました | Morgan Stanley | Overweight |
| 2022-09-21 | 開始されました | JP Morgan | Overweight |
| 2022-09-01 | 開始されました | Citigroup | Sell |
| 2022-06-17 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-06-16 | 開始されました | BofA Securities | Buy |
| 2022-04-28 | 開始されました | Credit Suisse | Outperform |
| 2022-02-18 | 開始されました | William Blair | Outperform |
| 2022-02-07 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-01-31 | 開始されました | Cowen | Outperform |
| 2022-01-07 | 開始されました | Piper Sandler | Overweight |
| 2021-10-05 | 開始されました | Guggenheim | Buy |
| 2021-09-24 | 開始されました | Stifel | Buy |
| 2021-06-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-11 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-07 | アップグレード | ROTH Capital | Neutral → Buy |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-03-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-12-22 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | 開始されました | Truist | Buy |
| 2020-10-14 | 開始されました | Wells Fargo | Overweight |
| 2020-09-18 | 開始されました | Goldman | Buy |
| 2020-02-28 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-02-14 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-11-01 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | 開始されました | Robert W. Baird | Outperform |
| 2019-06-10 | 開始されました | ROTH Capital | Neutral |
| 2019-05-03 | アップグレード | Wedbush | Neutral → Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2018-11-02 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-10-29 | 開始されました | Credit Suisse | Neutral |
| 2018-09-21 | 開始されました | Raymond James | Mkt Perform |
| 2018-05-15 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2017-11-01 | 繰り返されました | Jefferies | Buy |
| 2017-06-22 | 再開されました | Jefferies | Buy |
| 2017-03-28 | 開始されました | Chardan Capital Markets | Buy |
| 2016-08-05 | アップグレード | Jefferies | Hold → Buy |
すべてを表示
Intellia Therapeutics Inc (NTLA) 最新ニュース
Intellia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Dulac Edward J III - Moomoo
Intellia CFO Edward Dulac III sells $84,186 in stock - Investing.com
Intellia CFO Edward Dulac III sells $84,186 in stock By Investing.com - Investing.com Australia
Form 4 Intellia Therapeutics Inc For: 6 July By Investing.com - Investing.com Canada
Intellia Therapeutics (NTLA) VP sells shares to cover RSU tax - Stock Titan
Intellia (NTLA) CFO’s 4,677-share sale executed under 10b5-1 plan - Stock Titan
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Intellia lures 13 new employees with 53,250 stock awards - Stock Titan
More NTLA, Less RKLB: Cathie Wood’s Latest ARK Trades Explained - Stocktwits
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits
NTLAIntellia Therapeutics Inc Forecast, Target Price - Finviz
NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy - Stocktwits
Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy Now? - Yahoo Finance
Intellia Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
[144] Intellia Therapeutics, Inc. SEC Filing - Stock Titan
NTLA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57% - The Globe and Mail
Investor Sentiment Divided in Healthcare Sector: Intellia Therap - GuruFocus
Intellia Therapeutics (NASDAQ:NTLA): Can Innovation Justify the Buzz? - Kalkine Media
Price to book forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView
Price to earnings forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView
Price to book forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView
Enterprise value to revenue forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView
Enterprise value to revenue forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView
Price to sales forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView
Enterprise value to EBIT forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView
Price to sales forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView
Enterprise value to EBITDA forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView
Liquidity Mapping Around (NTLA) Price Events - Stock Traders Daily
Certain Stock Options of Intellia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-JUN-2026. - marketscreener.com
Price to earnings forward of Intellia Therapeutics, Inc. – BOATS:NTLA - TradingView
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics - The National Law Review
Investors who Lost Money on Intellia Therapeutics, Inc. (NTLA) Sh - The National Law Review
Intellia Therapeutics Inc (NTLA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Intellia Therapeutics Stock Short Interest Rises to 45.4% - Moomoo
Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest - Kavout | AI
Intellia Therapeutics, Inc. Actuals & Estimates (NASDAQ:NTLA) - TradingView
NTLA Stock Price, Quote & Chart - ChartMill
Levi & Korsinsky Reminds Intellia Therapeutics, Inc. Investors o - GuruFocus
Intellia Therapeutics, Inc. Actuals & Estimates (SWB:38I) - TradingView
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree - AOL.com
Intellia Therapeutics (NTLA) Short Interest & Short Float | Updated Jun 2026 $NTLA - MarketBeat
Intellia Therapeutics (NTLA) down 7.9% since last earnings report: Can it rebound? - MSN
Wall Street Expects This Growth Stock That's Already Climbed 70% to Almost Double -- And Here's Why. - AOL.com
Intellia Therapeutics Inc (NTLA) 財務データ
収益
当期純利益
現金流量
EPS
Intellia Therapeutics Inc (NTLA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Dulac Edward J III | EVP, Chief Financial Officer |
Jul 02 '26 |
Sale |
18.00 |
4,677 |
84,186 |
156,286 |
大文字化:
|
ボリューム (24 時間):